Literature DB >> 30106454

Estrogen enhances tumor growth and angiogenesis indirectly via mediation of bone marrow‑derived cells as well as directly through stimulation of tumor and endothelial cells.

Yingchen Zhuo1, Xueqian Li1, Qiaowei Zheng1, Xingjun Fan2, Wenbing Ma1, Jingguo Chen1, Xue Zhao1, Peipei Zhao1, Xuanlin Liu1, Fengru Tang1, Kai Cheng1, Weiyi Feng1.   

Abstract

Estradiol (E2) is a prime culprit for enhancing the progression of female hormone‑related cancers. Bone marrow‑derived cells (BMDCs) have been found to play a pivotal role in tumor growth. Estrogen receptors (ERs) are also found on certain subtypes of BMDCs, in addition to endothelial cells (ECs) and certain tumor cells. However, the role of BMDCs in E2‑induced tumor biology is still unclear. Thus, the effects of E2 on ER‑negative 4T1 breast cancer growth, the mobilization and recruitment of BMDCs, and interactions among BMDCs, ECs, and 4T1 cells were investigated. The results showed that E2 potentiated 4T1 tumor growth and angiogenesis in mice subjected to sham operation, ovariectomy (OVX), or OVX and E2 replacement treatment. E2 supplementation in mice with OVX upregulated the transcription of stromal cell‑derived factor‑1 (SDF‑1) mRNA in tumor tissues and enhanced the recruitment of BMDCs into tumor tissues in vivo. E2 deficiency significantly decreased proangiogenic CXCR4+, β3+, Sca‑1+ and CXCR4+β3+ BMDCs circulating in the peripheral blood. Cell‑based system analyses showed that E2 augmented the transcription of β3 mRNA in ECs, increased the adhesion of BMDCs to ECs. In addition, E2 enhanced the BMDC‑induced EC proliferation and migration, the BMDC‑induced 4T1 proliferation and the 4T1‑stimulated EC proliferation in addition to enhancing the proliferation of tumor cells and the migration of ECs in vitro. Therefore, E2 enhanced the growth of breast tumors by stimulating tumor cells and ECs directly, as well as by increasing proangiogenic BMDC mobilization and recruitment leading to augmentation of the tumor and EC functions indirectly by cell proliferation assay. These findings reveal a separate mechanism via which E2 promotes the growth of female hormone‑dependent tumors, which may be useful in explorations of new therapies for related cancers.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30106454     DOI: 10.3892/or.2018.6631

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  Copper-based metal-organic framework impedes triple-negative breast cancer metastasis via local estrogen deprivation and platelets blockade.

Authors:  Sijie Wang; Na Yin; Yongjuan Li; Tingting Xiang; Wenxiao Jiang; Xiu Zhao; Wei Liu; Zhenzhong Zhang; Jinjin Shi; Kaixiang Zhang; Xingming Guo; Pilei Si; Junjie Liu
Journal:  J Nanobiotechnology       Date:  2022-07-06       Impact factor: 9.429

2.  Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.

Authors:  Marta Araujo-Castro; Paola Parra Ramírez; Cristina Robles Lázaro; Rogelio García Centeno; Paola Gracia Gimeno; Mariana Tomé Fernández-Ladreda; Miguel Antonio Sampedro Núñez; Mónica Marazuela; Héctor F Escobar-Morreale; Pablo Valderrabano
Journal:  J Clin Med       Date:  2021-11-25       Impact factor: 4.241

Review 3.  Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.

Authors:  Madison Pereira; Kathy Matuszewska; Colin Jamieson; Jim Petrik
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-17       Impact factor: 5.555

4.  Micro-RNA193a-3p Inhibits Breast Cancer Cell Driven Growth of Vascular Endothelial Cells by Altering Secretome and Inhibiting Mitogenesis: Transcriptomic and Functional Evidence.

Authors:  Giovanna Azzarito; Lisa Kurmann; Brigitte Leeners; Raghvendra K Dubey
Journal:  Cells       Date:  2022-09-23       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.